The push could give CBD-based food additives and dietary supplements the green light.
The FDA has been collecting public comments since April to inform CBD product rules, and the window closes tomorrow. From state ag regulators to New York’s Bar Association, here are some highlights.
The agency, which will determine the future of the CBD industry, also provided an update on its information gathering. And yesterday, Canada’s health officials initiated a somewhat similar process.
Proposed legislation isn’t intended to bypass the FDA’s forthcoming national regulations. But with CBD products already on shelves, lawmakers can’t wait.
One unintended outcomes of last year’s Farm Bill: a mini-trend in smoking hemp.
"Across the United States, state and local regulators have been confronted with a huge onslaught of CBD.”
Should cannabidiol be regulated as a supplement, or a drug? Is it effective? Safe? Big business waits impatiently in the wings as the agency thinks through decisions to shape a multi-billion-dollar industry.
It’s more of an engagement and publicity stunt, but this one calls for ice cream fans to contact the FDA in support of CBD.
Canopy Growth selected a small, struggling county for its multimillion-dollar facility to produce hemp-derived CBD products.
A public meeting next month will focus on “scientific data and information about products containing cannabis or cannabis-derived compounds.”
Cannabis and hemp industry members have been awaiting clarity on the legality of hemp-derived CBD products following the passage of the 2018 Farm Bill that legalized hemp.
“If the FDA regulates too hard against CBD, it would really harm small Kentucky family farmers,” Ryan Quarles, Kentucky Ag Commissioner told the department.
Commissioner Scott Gottlieb's resignation this week spurred uncertainty, concerns over delays in the rollout of regulations for the hemp-derived CBD industry.
Several speakers listed key issues that the USDA should prioritize while drafting regulations for the newly legalized hemp industry.
From California to New York, state regulators and the FDA are pushing back against this major trend. Do they have the muscle?
An important finding may not be delivered in time for key UN commission’s vote this March.